Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 5/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791347 | 0.87 | NAMPT (0.64) | NAMPTROCK2ROCK1KDM4EL3MBTL1 | |
| SCHEMBL2791644 | 0.87 | NAMPT (0.64) | POLBNAMPTROCK2ROCK1PTPN1 | |
| SCHEMBL2792246 | 0.86 | POLB (0.59) | POLBSTAT3SMN1; SMN2NAMPTROCK2 | |
| SCHEMBL2792288 | 0.86 | NPC1 (0.57) | SMN1; SMN2NAMPTROCK2ROCK1KDM4E | |
| SCHEMBL2794381 | 0.86 | ROCK2 (0.64) | POLBSTAT3SMN1; SMN2NAMPTROCK2 | |
| SCHEMBL2791632 | 0.85 | NAMPT (0.63) | NAMPTROCK2ROCK1JAK2TYK2 | |
| SCHEMBL2792461 | 0.85 | ROCK2 (0.59) | NAMPTROCK2ROCK1KDM4EL3MBTL1 | |
| SCHEMBL2796251 | 0.84 | NAMPT (0.66) | POLBSMN1; SMN2NAMPTROCK2ROCK1 | |
| SCHEMBL2792488 | 0.84 | NAMPT (0.66) | NAMPTROCK2ROCK1KDM4EL3MBTL1 | |
| SCHEMBL2792854 | 0.83 | ROCK2 (0.60) | POLBSTAT3SMN1; SMN2NAMPTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | POLB 3020/4885STAT3 768/4885SMN1; SMN2 3334/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | POLB 3020/4885STAT3 768/4885SMN1; SMN2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.